Source:

Press Release

March 30, 2021
1 min watch
Save

Tarsus, LianBio to develop, commercialize TP-03 in Greater China

Source:

Press Release

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Tarsus Pharmaceuticals and LianBio have entered into a strategic partnership to develop and market TP-03 for the treatment of meibomian gland dysfunction and Demodex blepharitis in Greater China, according to a press release.

LianBio gains exclusive rights to develop and commercialize TP-03 (lotilaner ophthalmic solution 0.25%) in Greater China and will pay Tarsus $15 million upfront, the release said.

Tarsus may receive up to $185 million if it meets development and commercialization milestones, including $10 million by June 30 and $45 million over the next year for near-term clinical milestones, the release said. In addition, Tarsus may receive “tiered low double-digit royalties” based on TP-03 sales in Greater China and a minority stake in LianBio Ophthalmology depending on the milestone achievements.